FIGURE 4. (A) Immunofluorescence demonstrating colocalization of Eph B-4 and vWF in TEVG. (B) Immunofluorescence controls Western blotting (C) demonstrating Eph B-4 expression in BM-MNC, TEVG, and IVC, and graph showing densitometry.
Introduction:
The development of a living, autologous vascular graft with the ability to grow holds great promise for advancing the field of pediatric cardiothoracic surgery. Objective: To evaluate the growth potential of a tissue-engineered vascular graft (TEVG) in a juvenile animal model. Methods: Polyglycolic acid nonwoven mesh tubes (3-cm length, 1.3-cm id; Concordia Fibers) coated with a 10% copolymer solution of 50:50 L-lactide and ⑀-caprolactone were statically seeded with 1 ϫ 10 6 cells/cm 2 autologous bone marrow derived mononuclear cells. Eight TEVGs (7 seeded, 1 unseeded control) were implanted as inferior vena cava (IVC) interposition grafts in juvenile lambs. Subjects underwent bimonthly magnetic resonance angiography (Siemens 1.5 T) with vascular image analysis (www. BioimageSuite.org). One of 7-seeded grafts was explanted after 1 month and all others were explanted 6 months after implantation. Neotissue was characterized using qualitative histologic and immunohistochemical staining and quantitative biochemical analysis. Results: All grafts explanted at 6 months were patent and increased in volume as measured by difference in pixel summation in magnetic resonance angiography at 1 month and 6 months. The volume of seeded TEVGs at explant averaged 126.9% Ϯ 9.9% of their volume at 1 month. Magnetic resonance imaging demonstrated no evidence of aneurysmal dilation. TEVG resembled the native IVC histologically and had comparable collagen (157.9 Ϯ 26.4 g/mg), elastin (186.9 Ϯ 16.7 g/mg), and glycosaminoglycan (9.7 Ϯ 0.8 g/mg) contents. Immunohistochemical staining and Western blot analysis showed that Ephrin-B4, a determinant of normal venous development, was acquired in the seeded grafts 6 months after implantation. T he development of a living, autologous vascular graft with growth potential holds great promise for advancing the field of congenital heart surgery. Currently available synthetic vascular grafts, such as polytetrafluoroethylene, lack growth potential and present problems related to biocompatibility including thrombosis, ectopic calcification, and increased susceptibility to infection. 1 As a result, they are a cause of significant morbidity and mortality in modern pediatric cardiothoracic operations. 2 The lack of growth potential of currently used vascular conduits has resulted in the development of 2 surgical strategies: (1) delaying surgery until a patient has grown to a suitable size to allow for implantation of an adult-sized graft or (2) implantation of an oversized graft. Both strategies have deleterious effects on the patient. Delaying surgery results in prolonged exposure to hypoxia and volume overload. Chronic hypoxia can lead to developmental delay and failure to thrive, whereas volume overload can cause cardiac failure. 3 Use of oversized vascular grafts results in turbulent blood flow and increases the risk of thromboembolic complications, a leading cause of graft failure and postoperative morbidity and mortality. 4 In an initial clinical pilot study, the feasibility of using tissue-engineered vascular grafts (TEVGs) in the surgical repair of congenital cardiac anomalies has been clearly established. 5 This study demonstrated an excellent safety profile associated with the use of a TEVG constructed from biodegradable tubular scaffolds statically seeded with autologous bone marrow-derived mononuclear cells (BM-MNC) as large caliber venous conduits in a low-pressure, high-flow, circulatory system. Furthermore, this study demonstrated an increase in size of the TEVG when implanted in juvenile recipients raising the question of whether this increase in size was the result of growth or aneurysmal dilation.
Conclusions
In this investigation we evaluated the development of these TEVGs using a juvenile lamb model. Specific focus was placed on elucidating the mechanisms by which these grafts increase in size over time. Graft size and morphology were serially evaluated using magnetic resonance imaging (MRI) over a 6-month time course and an extensive histologic, biochemical, and molecular analysis of the grafts was performed to characterize the neotissue from the perspective of vascular growth and development.
Despite the clear functional efficacy of TEVG, the mechanisms underlying vascular neotissue formation remain poorly understood, in part because of an incomplete characterization of the fully formed tissue-engineered neovessel. A better understanding of these phenomena will be critical to the continued development of this promising technology and the development of the first man-made vascular graft with growth potential.
MATERIALS AND METHODS

Scaffold
Nonwoven polyglycolic acid mesh tubes (1.3-cm internal diameter, 1.5-mm thick) ͓Concordia Fibers (Coventry, RI)͔ were cut to a length of 3 cm and coated with 10% (wt/vol) copolymer solution of 50:50 L-lactide and ⑀-caprolactone ͓P(CL/LA)͔ in 1,4-dioxane. The conduits were then freeze-dried under vacuum pressure. Porosity was determined by imaging with scanning electron microscopy (FEI corp, Model XL-30). Tensile strength was measured using tensiometry (Instron Model 5543).
Bone Marrow-Derived Mononuclear Cells
BM-MNC were isolated as described previously. 6 Briefly, 50 mL of bone marrow was aspirated from the sternum of juvenile Dover lambs into a heparinized syringe (100 U/mL), diluted 1:4 in phosphate buffered saline (PBS), and passed through a 100-m filter to remove any fat or bone fractions. BM-MNC were obtained by centrifuging the sample on a histopaque density gradient (Sigma) for 30 minutes at 2700 rpm. Cells yield and viability were determined by staining the cells with trypan blue and quantifying with a hemocytometer.
Seeding Technique
Polyglycolic acid coated with a copolymer of polycaprolactone and polylactic acid (PGA/P[CL/LA]) scaffolds were sterilized in a 10% pencillin/streptomycin solution for 24 hours under direct ultraviolet light. 7 Scaffolds were then washed in sterile PBS and statically seeded with BM-MNCs (approximately 1 ϫ 10 6 cells/cm 2 ). Grafts were incubated (37°C, 5% CO 2 , 95% relative humidity, 760 Torr) for a minimum of 2 hours in autologous serum.
Juvenile Lamb Intrathoracic Inferior Vena Cava Replacement Model
The animal care and use committee at the Yale School of Medicine approved the use of animals for this experiment. All animals received humane care in compliance with the "Guide for the Care and Use of Laboratory Animals" published by the National Institutes of Health. Eight TEVGs were implanted as inferior vena cava (IVC) interposition grafts. 8 Juvenile lambs were anesthetized with 2%-4% isofluorane. The right chest wall was opened along the seventh intercostal space and the IVC was exposed and heparin (100 U/kg) was administered intravenously. The TEVG was sewn in as a vascular interposition graft using standard continuous technique. Hemostasis was obtained, and the incision was closed.
Magnetic Resonance Imaging Methods
Postoperatively, each animal was imaged bimonthly for 6 months. Magnetic resonance imaging (MRI) was performed using a Siemens Sonate 1.5 T MR Scanner. 1.5 T MRA was performed using a 3D MPRAGE acquisition with 25-cm FOV, 1.1-mm slice thickness, 128 slices, TE ϭ 3 milliseconds, TR ϭ 24 milliseconds, 2 averages, alpha ϭ 45, 192 ϫ 256 matrix and bandwidth ϭ 220 Hz/pixel. The data were analyzed with BioImage Suite software (www.bioimagesuite.org). All images were reoriented so the IVC was parallel to the y axis of the images; the images were resampled to have dimensions 101 ϫ 256 ϫ 101 and isotropic voxel size equal to 0.78125 mm.
Anastomotic sites were identified and confirmed with gross images. We used a nonrigid registration technique to compute regional voxel expansion between image pairs (1 and 6 months post TEVG implantation). These expansion measures were integrated over the area of the graft to yield the average volumetric graft expansion. The change in size between the 1-month TEVG volume and 6-month TEVG was expressed as the ratio of the 6-month TEVG volume over the 1-month TEVG volume. The same method was used to measure the change in volume of the right pulmonary artery, which served as a control.
Histology and Immunohistochemistry
Cross-sectional samples of the TEVG were fixed in 10% formalin and embedded in paraffin. Five micron sections were stained using standard techniques for hematoxylin and eosin, von Kossa (calcium), Masson's Trichrome (collagen), Alcian Blue and Movat's Stains (glycosaminoglycans), and Verhoeff-van Gieson (elastin).
Immunohistochemical staining was performed using standard streptavidin-biotin detection. Primary antibodies were used to identify endothelial cells (rabbit-antihuman von Willebrand Factor (vWF, Dako), and smooth muscle cells ͓mouse-antihuman smooth muscle actin (SMA, Dako)͔. Both antibodies cross react with ovine tissue. Positive expression was detected using 3,3-diaminobenzidine (Vector), and nuclei were counterstained with hematoxylin. Vessel morphometry including determination of graft wall thickness were determined.
Eph-B4 Analysis Immunofluorescence
Samples were fixed with 4% paraformaldehyde, embedded in OCT, and 6-mm sections were cut. Primary antibodies included Eph-B4 (Santa Cruz), and vWF (Dako). Alexa Fluor 488 and 568 were used for fluorescence detection. All samples were counterstained with 4', 6-diamidino-2-phenylindole (DAPI). Images were captured with an Axioimager A1 (Carl Zeiss) under identical conditions.
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Western Blotting
Native IVC and TEVG were pulverized on dry ice, immersed in lysis buffer, and centrifuged for 60 minutes at 4°C and then at 12,000 g for 10 minutes at 4°C. Samples analyzed were typically 40 g.
Biochemical Analysis
TEVG sections were frozen and lyophilized for quantitative biochemical analysis.
Collagen
Collagen content was determined by measuring hydroxyproline content as described previously. 9 Briefly, native IVC and TEVG were digested at 120°C in NaOH (1.33 N). Each sample was then incubated in chloramine T dissolved in N-propanol and acetate citrate buffer (25 minutes, room temperature), followed by incubation in Ehrlich's reagent (65°C, 20 minutes). Total collagen content was determined by multiplying the hydroxyproline content by a factor of 7.5.
Elastin
Elastin content was determined using a Fastin colometric assay (Biocolor Assays, Inc.). Briefly, 4 to 6 mg of sample tissue was digested 3 times in 0.25 M oxalic acid (Ͼ90°C, 60 minutes). Each digestion included an elastin-precipitating agent; the precipitate was reacted with an elastin-binding dye that was detected with spectrometry (513 nm) and compared with a standard curve.
Glycosaminoglycan
Glycosaminoglycan content was determined in triplicate using a Blyscan colorometeric assay (Biocolor Assays, Inc.). Four to 6 mg of tissue were digested in papain. Precipitates were missed with a glycosaminoglycan-binding dye that was detected by spectrometry (656 nm) and compared with a standard curve.
RESULTS
Scaffold
The scaffold was approximately 80% porous with pore sizes ranging from approximately 5 to 200 m.
The ultimate tensile strength of the unseeded scaffold measured 9.16 Ϯ 0.62 MPa with an elastic modulus of 0.35 Ϯ 0.01 MPa.
Cells
The BM-MNC isolation method described above resulted in the isolation of between 1-10 Ϯ 10 7 cells with cell viability in excess of 90% as determined using hemocytometry and trypan blue exclusion. Cells were seeded on the scaffold and implanted as an interposition graft in the suprahepatic IVC in juvenile lambs. All lambs fully recovered from the procedure and grew and developed normally.
Magnetic Resonance Imaging
Our analysis using nonrigid registration of the 3-dimensional serial images revealed overall graft enlargement over 6 months. All grafts increased in size as determined by volume measurement. Mean corrected graft growth in volume was measured to be 126.9 Ϯ 9.9% over 6 months (Fig. 1 ). The mean corrected growth for the right pulmonary artery over the same period in time was 140 Ϯ 12%.
Histology and Immunohistochemistry
Qualitative histologic analysis performed at 6 months revealed a laminated structure with 3 layers that correspond to the intima, media, and adventitia (Fig. 2 ). Graft wall thickness measured 1.1 mm, which was similar to the native IVC wall thickness (1.0 mm). The inner layer was composed of a monolayer of vWF-staining cells consistent with the formation of an endothelial monolayer. The inner endothelial monolayer was surrounded by concentric layers of smooth muscle actin-positive cells consistent with an organized medial layer of smooth muscle cells. The outer structural layer was rich in extracellular matrix including areas positively staining with Movat stain demonstrating collagen, Verhoeff-Van Gieson stain demonstrating elastin, and Alcian blue stain demonstrating glycosaminoglycans (Fig. 3) . The von Kossa stain demonstrated minimal areas of ectopic calcification scattered throughout of the graft. 
Expression of Eph-B4 in TEVG
Because Eph-B4 is a determinant of veins that has been described during embryonic and young animal development, we examined whether Eph-B4 was present on TEVG in our lamb model. 10, 11 Eph-B4, a venous marker, was not expressed in the TEVG before implantation but was expressed strongly in the endothelium of the TEVG 6 months after implantation. Eph-B4 expression colocalized with vWF expression, indicating its expression in the endothelial lining. 10, 11 Western blot analyses confirmed the Eph-B4 expression in TEVG. Eph-B4 protein was detected in the 6-month TEVG, although less than in the native IVC (Fig. 4) . 
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Biochemical Analysis Biochemical Assays
All TEVGs contained similar amounts of collagen when compared with native ovine IVC (157.9 Ϯ 26.4 g/mg and 136.7 Ϯ 13.8 g/mg dry weight, respectively). Interestingly, the unseeded TEVG on an average contained more collagen than the native IVC or seeded TEVG.
Elastin content of seeded TEVG averaged 186.95 Ϯ 16.7 g/mg dry weight of tissue. This represents a 47.2% increase in elastin content over the unseeded scaffold, which contained 126.97 Ϯ 36.78 g/mg dry weight. However, the seeded grafts contained less elastin at 6 months compared with native ovine IVC (365.78 Ϯ 44.55 g/mg).
Glycosaminoglycan content of tissue-engineered scaffolds was routinely greater than native IVC. There was no statistically significant difference between seeded and unseeded specimens, each reaching glycosaminoglycan levels between 9.7 Ϯ 0.8 g/mg and 11.8 Ϯ 4.3 g/mg dry weight, respectively (Fig. 3 ). Native IVC contained 4.9 Ϯ 0.2 g glycosaminoglycan/mg dry weight.
DISCUSSION
Previous clinical studies investigating the use of TEVG in the surgical repair of congenital cardiac anomalies have demonstrated that the conduit created by seeding autologous BM-MNC onto a biodegradable tubular scaffold fabricated from polyglycolic acid fiber mesh coated with a 50:50 copolymer of L-lactone and ⑀-caprolactone increased in size over time. 5 In this investigation, we evaluated the growth potential of TEVG by implanting them as IVC interposition grafts in a juvenile lamb model in an attempt to determine if this increase in size represented growth or aneurysmal dilation. We serially monitored graft volume in vivo using MRI before harvesting the grafts. We subsequently harvested the conduits and characterized the resulting vascular neotissue in an attempt to identify any pathologic changes and to compare the neotissue with native tissue. Results of this study demonstrate that the TEVG functioned well without evidence of graft thrombosis, rupture, or significant ectopic calcification. Using serial MRI, we were able to demonstrate that the TEVG increased in size proportional to the native right pulmonary artery. Using qualitative immunohistochemistry, we were also able to show that by 6 months the TEVG resembled the native IVC including similar wall thickness and possession of a laminated tubular morphology with an inner monolayer of endothelial cells surrounded by several layers of smooth muscle cells concentrically arranged circumferentially around the lumen. Furthermore, using quantitative biochemical analysis, we showed that the extracellular matrix of the TEVG resembled the extracellular matrix of the native IVC resulting in a TEVG with a biomechanical profile similar to the native IVC. Interestingly, by 6 months, TEVG expressed Eph-B4, a marker of venous differentiation, suggesting the formation of venous vascular neotissue when the TEVG is implanted in the venous circulation. This marks the first time a TEVG has demonstrated molecular evidence of normal vascular development.
Arteries and veins are defined in the adult by their functional and anatomic differences. 12 However, the molecular differences between arteries and veins are established before the onset of circulation. 13 Molecular differences between arterial and venous endothelial cells have been demonstrated during embryonic development in the chick, mouse, and zebrafish. [13] [14] [15] There are several critical molecular determinants of blood vessel development, the most well described of which are Ephrin-B2 for arterial development, and Eph-B4 for venous development. 16 -18 The Eph receptors comprise the largest of the 14 families of receptor tyrosine kinases in mammals and are activated by ligands of a similarly large Ephrin family. After their initial discovery as orphan receptors by Bennett et al in 1995, Eph receptors were found to have matching Ephrin ligands, and early research efforts determined that Ephrins and Ephs participate in developmental processes. 19 Remarkably, in contrast to other ligands that are uniformly expressed throughout the circulatory system, Ephrin-B2 was found to be specifically expressed only by arteries, whereas Eph-B4, one of its receptors, is expressed only on veins. 11, 13, 20 These data provided one of the first examples of a genetic distinction between these 2-vessel subtypes and suggested that Ephrin-mediated interactions may be essential for angiogenesis. 12, 21 Our data, that Eph-B4 is not present in the preimplantation TEVG but is expressed by 6 months in the developing TEVG, strongly support the concept that the TEVG is growing with "normal" patterns of gene expression. The increased expression of Eph-B4 may be due to the juvenile environment of the young lambs, because transfer of adult veins into adult arterial environments is associated with loss of Eph-B4 expression. 22 We believe that induction of Eph-B4 expression in the growing TEVG is the first example of nonmalignant Eph-B4 induction after postnatal development.
This study possesses several inherent limitations. The most significant limitation is lack of a standard definition of growth as opposed to aneurysmal dilation. For the purpose of this investigation, we defined growth as an increase in size without evidence of pathologic change in morphology. From the translational perspective, this distinction is more semantic than real so long as the TEVGs do not increase in size beyond the native vessels or result in rupture. It is important to note that neither increase in graft size beyond the native vessel nor rupture of a TEVG has been reported when TEVGs were implanted in low pressure circulatory systems such as the venous, pulmonary, or Fontan circulation. 5, 23 A second limitation is that the IVC is a capacitance vessel, the size of which is directly related to the hydration status of the graft recipient. To minimize this effect, we standardized the animals feeding and hydration regimen to prevent dehydration of over-hydration at the time of imaging. Identification of the anastomotic sites became more challenging as the vessels grew. To validate our selection of the proper anastomotic sites, the MRI images were compared with digital images of the IVC taken immediately at sacrifice on the same day as the 6-month MRI. Finally, there were 2 options available to us in terms of quantifying vessel growth. The obvious method would have been to have performed a manual segmentation of graft volume from the images at each time point and simply compare the volumes directly. This, however, suffers from the uncertainty in manually defining the edges of the grafts (ie, where the graft blends in to the native vessel) separately at each image, and could be a major source of error in the comparison. The method we choose instead defined the graft only in one time point and used a nonrigid registration algorithm to map this graft to the next time, relying on image similarity as the criterion for the mapping. The maps are relatively smooth and result in a method that is relatively robust to the exact delineation of the graft.
Previous studies have demonstrated the growth potential of other types of TEVG in the pulmonary circulation. 24, 25 These studies, however; used a different cell source, seeding the biodegradable tubular scaffolds with autologous endothelial cells and myofibroblasts instead of BM-MNC. Additional work by our group has demonstrated that the TEVG described in this study resulted in the formation of neovessels that not only resembled native vessels morphologically and histologically but also functionally possessed a smooth muscle layer that was responsive to pharmacological stimulation and a functional endothelium that inhibits thrombosis. 23 Taken together, these studies suggest that tissue engineering technology offers the ability to create vascular grafts that are living structures capable of growth, repair, and remodeling in response to their local environment milieu. Continued investigation into the mechanisms underlying the process of vascular neotissue formation is essential to gain insights that will enable us to rationally design improved TEVG, to promote the continued translation of this promising technology, and enable it to reach its full potential for advancing the surgical treatment of congenital heart disease.
Discussions
DR. JOSEPH P. VACANTI (BOSTON, MASSACHUSETTS): Vascular reconstruction and vascular replacement are emblematic of the enormous progress and innovation of 20th and 21st century surgery. Beginning with Carrel, many materials have been used for arterial, venous, and cardiac replacement structures. Homografts, autografts, xenografts, processed or living, synthetic or natural materials, or combinations of those have also been used to create vascular conduits.
In 1986, Weinberg and Bell built a living vascular conduit from cells in a contracted collagen Matrix. This opened the door for fabrication of a living vascular replacement for potential human use. Your Yale group has built a program in tissue engineering addressing important questions toward safe clinical application in a careful scientific and multidisciplinary approach to the problem.
The problem of growth is very important for all of us involved in the surgical care of children. I have 2 questions. First, can you elaborate on your definition of aneurysmal change or true growth and how can we determine this over time? Second, can you give us insight on the bursting pressures of your structures, which clearly in these applications are in the low pressure circuit? And can you comment on where you and the field stand regarding living arterial replacement that would require obviously much higher bursting strengths?
DR. K. CRAIG KENT (NEW YORK, NEW YORK): I have a couple of quick questions.
At any point did you institute a control where you implanted just the bio-resorbable graft but without seeding? I am interested in understanding the importance of seeding relative to the graft scaffolding in this process.
My second question is about the potential for aneurysmal growth of the graft. You have a 6-month follow-up, but you are planning on placing these in children, and thus they need to last for many years. How do you know that that growth that you observed over 6 months is not just the beginning of aneurysmal growth? DR. MICHAEL E. ZENILMAN (BROOKLYN, NEW YORK): About 10 years ago Langer reported in the journal Science (Niklason et al, Science 284:489 -493, 1999) the technique to construct an artery using a polyglycolic acid scaffold, which was first seeded with smooth muscle cells and then endothelial cells. But the secret, in my mind, was that they grew the grafts for a few weeks in vitro in a pulsatile environment. Is there a similar environment in which you needed to grow your grafts for them to act as veins? Do they have to be in a pulsatile system? Do they have to experience flow around them?
DR. CHRISTOPHER K. BREUER (NEW HAVEN, CONNECTICUT):
In response to your first question, how did we define growth versus aneurysmal dilatation, for the purpose of this study we defined growth as a proportional increase in size that did not exceed the size of the surrounding native vessel. We also tried to evaluate the neotissue that formed, comparing it with native tissue and trying to identify if there were any pathologic changes.
Pragmatically, though, this is much less of an important question and in many ways just a semantic issue. The real question at hand is whether these grafts continue to dilate and rupture. From our preclinical data and from our clinical data I can tell you that they do not. We performed over 200 animal experiments implanting tissue-engineered grafts similar to the grafts described in this presentation and have no history of aneurysm formation or graft rupture. Additionally, in the clinical pilot study, 25 patients were implanted with these tissue-engineered grafts and followed up to 6 years, and again there has been no evidence of aneurysm formation or graft rupture.
With regard to the burst pressure of these grafts, I was clearly interested in expanding this technology from the venous system to the arterial system. The need for improved grafts for angioaccess and small caliber arterial bypass grafting is quite evident. If we take the same graft described in this presentation and use it as an arterial interposition graft, it does form an aneurysm and ruptures within a 2-to 3-week period. However, we have taken steps toward improving the design of this graft for application as an arterial graft. We have done this along 2 fronts.
The first front, we looked at scaffold design and took a biomaterials approach. By replacing the polyglycolic acid fiber that forms the basis of our scaffold with a polylactic acid fiber that has essentially the same biomechanical properties but degrades more slowly, we can form an arterial conduit using the same technique that does not rupture. It turns out that the basis of the biomechanical strength of these grafts initially is completely determined by the scaffold, but as time goes on becomes more and more determined by the extracellular matrix produced by the neotissue. By the time the scaffold is completely degraded the neotissue is what determines the scaffold strength. So it is really a balancing act trying to coordinate the degradation of your polymer with the formation of the tissue.
The second approach that has been adopted in attempting to do this is the formation of a bio-reactor. This is an incubation system that is set up for ex vivo neotissue development. A seeded scaffold can be placed in the system and exposed to biomechanical forces that influence the cells and cause them to create an extracellular matrix that is more robust and can withstand higher pressures. This technique also resulted in the formation of a graft that can be used for replacement of arteries.
As far as where we are at with regard to the clinical trial, our pilot study was performed by my collaborator, Toshiharu Shinoka, at Tokyo Women's Hospital in Japan. He and I developed this technique while working in Dr. Vacanti's laboratory in the early 1990s, and we are currently working with the FDA on the design of our trial to be performed at Yale.
With respect to the question regarding a control that is unseeded, in this experiment we did have an unseeded control and it did form a stenotic vessel. In the mouse studies we noted some things that were very interesting and have resulted in what I believe will be the next generation of tissue-engineered grafts.
If you look at all unseeded scaffold placed in the mouse model, about 80% of them will fail because of stenotic failure over a 10-to 12-week time period. But interestingly, about 20% of these grafts will remain patent.
We have done cell tracking experiments using species specific immunohistochemical stains-we take advantage of the fact that it is a chimera model with a human blood vessel. The cells do, in fact, attach to the scaffold and are initially incorporated in the neotissue; however, they are ultimately replaced by the host cells.
We have gone on to look for potential ways in which the seeded cells could result in the formation of patent grafts and have noted that these cells actually secrete chemokines that recruit the host cells and result in good graft formation. Finally, we were able to use controlled release technology to release some of these chemokines from an unseeded scaffold and can actually get grafts that behave just as well as the seeded scaffold. We believe this will have important implications for the translation of this technology because it will improve the off-the-shelf availability of these grafts and improve their overall utility.
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